Company Overview

Colinz Laboratories Limited (CIN: L24200MH1986PLC041128) published its 40th Annual Report for the financial year ended March 31, 2026. The company is engaged in manufacturing and marketing pharmaceutical formulations, particularly in the gynecological sector.

Financial Performance (FY 2025-26)

  • Total Revenue: ₹662.05 Lacs (Previous year: ₹682.56 Lacs)
  • Revenue from Operations: ₹613.61 Lacs (Net of GST)
  • Other Income (Interest and Dividend): ₹48.44 Lacs
  • Total Expenses: ₹593.14 Lacs (Previous year: ₹620.62 Lacs)
  • Profit Before Tax: ₹68.91 Lacs (Previous year: ₹61.94 Lacs)
  • Tax Expense: ₹17.46 Lacs
  • Net Profit: ₹51.45 Lacs (Previous year: ₹49.66 Lacs)
  • Other Comprehensive Income: ₹5.42 Lacs
  • Total Profit After Tax & OCI: ₹56.87 Lacs
  • Balance Carried to Balance Sheet: ₹462.50 Lacs

Operational Review

The financial year 2025-26 was challenging for the pharmaceutical industry due to geopolitical disturbances impacting raw material supplies and inflation. Despite these challenges, the company maintained operations with production being done on third-party/loan license basis after disposal of its factory premises.

Dividend

No dividend was recommended for FY 2025-26 to plough back surplus and strengthen financial resources.

Share Capital

Paid-up equity capital remained unchanged at ₹251.91 Lacs as on March 31, 2026. No shares were issued during the year.

Material Changes Affecting Financial Position

The company sold its factory premises situated at Sinnar, Nasik on June 18, 2026, for a consideration of ₹4 Crores as per sale agreement. The transaction was completed pursuant to approvals obtained from the Board of Directors and/or Members. The accounting impact including gain/loss on sale will be recognized in accordance with applicable Accounting Standards.

Board of Directors Changes

  • Dr. Mani L.S. (DIN: 00825886), Director & Company Secretary, passed away on November 7, 2025
  • Mrs. Vijaya Mani (DIN: 11363910) was appointed as Additional Director (Promoter, Non-Executive) effective November 11, 2025
  • Mr. N.K. Menon (DIN: 01111297) continued as Whole-Time Director & CEO
  • The Board comprised Mrs. Vijaya Mani, Mr. N.K. Menon, CA Bhavik A. Shah (Independent Director), and Shri B.B. Dias (Independent Director)

Key Managerial Personnel

  • Mr. N.K. Menon: Whole-Time Director & CEO
  • Dr. Mani L.S.: Director & Company Secretary (till November 7, 2025)
  • Mrs. Falguni Kumawat: Company Secretary & Compliance Officer (w.e.f. December 1, 2025)
  • Mr. Ganesh Chitte: CFO

40th Annual General Meeting

The 40th AGM is scheduled for Tuesday, September 22, 2026, at 2:30 PM IST through Video Conferencing/OAVM. The registered office at A-101, Pratik Industrial Estate, Mulund-Goregaon Link Road, Bhandup(W), Mumbai - 400 078 will be deemed the venue.

Agenda Items:

1. Adoption of Audited Financial Statements and Reports

2. Re-appointment of Mr. N.K. Menon who retires by rotation

3. Appointment of Mrs. Vijaya Mani as Director (Non-Executive, Non-Independent)

4. Re-appointment of Mr. N.K. Menon as Whole-Time Director & CEO and remuneration approval

Remuneration Proposal for Mr. N.K. Menon

The Board proposed re-appointment of Mr. N.K. Menon as Whole-Time Director & CEO for one year from October 1, 2026 to September 30, 2027 with remuneration not exceeding:

  • Salary: ₹7.5 to ₹12.50 Lacs p.a.
  • Allowances and Perquisites: ₹7.50 Lacs p.a.
  • Additional benefits: Gratuity (15 days' salary), insurance premiums, mediclaim as per company rules

Shareholding Pattern

  • Mrs. Vijaya Mani: 1,248,500 shares (49.56%)
  • Mr. N.K. Menon: 100 shares
  • Dematerialized shares: 73.44% of total equity
  • Register of Members will remain closed from September 15, 2026 to September 22, 2026

Corporate Governance

  • Board Meetings: 8 meetings held during the year
  • Audit Committee Meetings: 6 meetings held
  • The company complied with Secretarial Standards SS-1 and SS-2
  • No frauds were reported by auditors under Section 143(12) of Companies Act, 2013

Auditors

  • Statutory Auditors: Vora & Associates, Chartered Accountants (FRN: 111612W)
  • Secretarial Auditor: CS Sanjay R. Dholakia (M. No. 2655/CP No. 1798)
  • Internal Auditor: Ajay Sharma & Associates

Other Disclosures

  • No deposits accepted under Section 73 of Companies Act, 2013
  • No loans, guarantees or investments under Section 186
  • No CSR obligations applicable
  • No material orders passed by regulators/courts
  • No unclaimed dividend to transfer to IEPF

Future Outlook

The company continues to focus on judicious working capital management and maintains a debt-free status. The pharmaceutical sector remains competitive with pricing controls, but the company's products enjoy good brand recognition among gynecologists.